Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


August 02, 2015 9:22 PM ET

Biotechnology

Company Overview of Caladrius Biosciences, Inc.

Executive Profile

Hans S. Keirstead Ph.D.

Chief Science Officer, Senior Vice President of Research and President of Neostem Oncology, Caladrius Biosciences, Inc.
AgeTotal Calculated CompensationThis person is connected to 5 Board Members in 5 different organizations across 7 different industries.

See Board Relationships
----

Background

Dr. Hans S. Keirstead, PhD serves as the President of NeoStem Oncology, Senior Vice President of Research and Chief Science Officer at Caladrius Biosciences, Inc. (formerly Neostem, Inc.) Dr. Keirstead serves as Chief Executive Officer and President at California Stem Cell, Inc. Dr. Keirstead founded Ability Biomedical Corporation and serves as its President and Chief Executive Officer. Dr. Keirstead served as Chief Executive Officer of Neuron Therapeutics, Inc. since ...

Corporate Headquarters

420 Lexington Avenue
New York, New York 10170

United States

Phone: 212-584-4180
Fax: 646-514-7787

Board Members Memberships

President, Chief Executive Officer, and Director
2014-Present
Director

Education

Doctorate
University of Cambridge
PhD
University Of British Columbia

Other Affiliations

Annual Compensation

There is no Annual Compensation data available.

Stocks Options

There is no Stock Options data available.

Total Compensation

There is no Total Compensation data available.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Gil Van Bokkelen Ph.D.Co-Founder, Chairman and Chief Executive Officer
Athersys, Inc.
$599.8K
Robin C. Stracey Chief Executive Officer and Director
Cesca Therapeutics Inc.
--
Marc H. Hedrick M.D.Chief Executive Officer, President, Director and Member of Executive Committee
Cytori Therapeutics, Inc.
$437.4K
Martin M. McGlynn Chief Executive Officer, Director, Member of Strategic Transactions Committee, Chief Executive Officer of Stemcells California Inc and President of Stemcells California Inc
StemCells Inc.
$789.5K
Andrey Semechkin Ph.D.Co-Chairman and Chief Executive Officer
International Stem Cell Corporation
$246.1K
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Caladrius Biosciences, Inc., please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.